Trial Profile
Efficacy and Safety Study of GB-0998 for Guillain-Barre Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2016
Price :
$35
*
At a glance
- Drugs Immunoglobulin G (Primary)
- Indications Guillain-Barre syndrome
- Focus Therapeutic Use
- Sponsors Japan Blood Products Organization
- 03 Feb 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 22 Jan 2015 New trial record